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Antiretroviral therapy (ART) in HIV infected pregnant women contributes to 
the prevention of HIV transmission to the newborn. However, as ART can also 
induce HIV drug resistance during suboptimal levels of virological suppression a 
major concern is the subsequent risk for transmitted drug resistant (TDR) virus to the 
child.  In Honduras and Belize, like in many other countries around the world, mono-
therapy was used to prevent mother-to-child transmission of HIV-1 (MTCT) until 
relatively recently when it was changed to a more effective combination antiretroviral 
therapy (cART). Prior to this study there was no information about antiretroviral drug 
resistance in HIV-1 infected women and children in Honduras and Belize, and limited 
data other from parts of Latin America. The first aim (Paper I) was to evaluate the 
prevalence of drug resistance in HIV-1 infected infants born in Honduras and Belize 
between 2001 to 2004, before cART was implemented for prevention of MTCT. 
Genotypic resistance was performed by sequencing of the HIV pol region and was 
successfully in dried blood spots from 66 HIV-1-infected infants (55 from Honduras 
and 11 from Belize). Mutations associated with antiretroviral drug resistance were 
detected in sequences from 13% of the Honduran infants and 27% of Belizean 
infants. Thus the study documented, for first time, the presence of drug resistance in 
HIV-1 infected Honduran and Belizean infants. Resistance probably was transmitted 
from the mothers since none of the infants had received antiretroviral drugs as 
prophylaxis or therapy.  
The second aim (Paper II) was to evaluate antiretroviral drug resistance in 
pregnant HIV-1-infected women in Honduras and risk for MTCT subsequent to ART 
prophylaxis. In addition, we investigated changes in immune activation during 
pregnancy by evaluating LPS levels. A total of 50 mother-child pairs and 95 HIV-
negative pregnant women were enrolled. The presence of antiretroviral drug 
resistance was monitored in samples drawn during pregnancy and shortly after 
delivery. Twenty-nine women (58%) were treatment-naïve at study entry and started 
antiretroviral prophylaxis against MTCT during pregnancy while 21 women were 
already identified as HIV-1 infected and on ART at study entry. Antiretroviral drug 
resistance was detected in 20% of the samples obtained from the mothers at baseline; 
10% among treatment-naïve patients and 29% among treatment-experienced patients. 
Furthermore, despite ART prophylaxis 22 of 50 (44%) women were viremic. No 
MTCT were observed, but still the high prevalence of resistance and viremia 
indicated that there was a significant risk for MTCT. The LPS levels declined 
between pregnancy and after delivery in the HIV-1 infected women indicates that 
pregnancy might influence the LPS levels, a novel finding that merits further 
investigation. This study demonstrated for the first time a high prevalence of 
antiretroviral drug resistance and viremia in pregnant Honduran women, which could 
limit the effectiveness of antiretroviral prophylaxis against MTCT. 
Taken together the studies indicate that there is a need for improvements of 
prevention against MTCT in Belize and Honduras. This includes better access to 
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1 EPIDEMIOLOGY OF HIV-1 INFECTION 
 
1.1  GLOBAL SITUATION OF HIV-1 
Infections with the human immunodeficiency virus (HIV) have become one of 
the major health problems in the world. At the end of 2011, it was estimated that 34 
million people were living with HIV, around 2.5 million became infected, and 1.7 
million died of the disease [1]. HIV-1 is transmitted in human body fluids by three 
major routes: sexual intercourse [2, 3], direct injection with the virus-contaminated 
fluids [4, 5], and by vertical transmission [6, 7]. Sexual intercourse constitutes the 
main infection route, accounting for 80% of the infections worldwide. Heterosexual 
transmission is the most frequent transmission route and 70% of all infections are 
acquired through this route [8-10].  
Among the total of HIV infected people worldwide at the end of 2011, 23.5 
million are residents in Sub-Saharan Africa infected mainly through heterosexual 
transmission [1]. The worst affected country on this continent is South Africa, which 
has 5.6 million infected inhabitants [11]. A large number (4 million) of infected people 
are also living in South-East Asia of which 50% are concentrated in India [12, 13]. In 
most Asian countries the main transmission routes are through injecting drug use 
(IDU), female sex workers (FSM), and men who have sex with men (MSM) [1]. In 
Eastern Europe and Central Asia the number of infections is rising, reaching 1.4 million 
in 2011, mainly among IDUs, and their sexual partners [12]. After Sub-Saharan Africa 
the region with highest HIV prevalence is the Caribbean, where the Bahamas is the 
nation with the highest prevalence of HIV (3%), heterosexual transmission, is 
considered the main mode of acquisition of HIV [11, 14]. In Latin America around 1.4 
million people were estimated to be living with HIV and there were an estimated 
83,000 new infections and 67,000 deaths of AIDS [1, 11]. The highest rates of HIV 
infection in Latin America are found among MSM, but infection in women and certain 
ethnics groups is rapidly growing [15].    
 
1.2 GLOBAL HIV-1 SITUATION IN WOMEN AND CHILDREN  
The HIV epidemic is a heavy toll on women and children worldwide. At the 
end of 2011 it was estimated that half of all HIV-1 infected individuals are women 
[16]. Generally the main transmission mode for HIV in women is through 
heterosexual contacts [17]. Globally, HIV/AIDS is the leading cause of death among 
women of reproductive age. In regions such as sub-Saharan Africa and the Caribbean, 
women are more affected by HIV than men. For Asia and Latin America, 
approximately 35 percent of adults living with HIV and AIDS are women [11].  
One of the most devastating effects of the HIV epidemic has been seen in 
children. According to the 2012 UNAIDS report, at the end of 2011, there were 3.3 
million children living with HIV around the world. An estimated 330,000 children 
became newly infected with HIV. Almost all of these infections occur in low and 
middle-income countries [1]. Today, over 25 million children under the age of 15 
have lost one or both parents by HIV/AIDS; compared to 1990 when fewer than one 
million children under the age of 15 were orphaned for this reason [18]. 
 
1.3 HIV-1 AND AIDS IN HONDURAS AND BELIZE 
With an area of about 112,492 km², Honduras is strategically located in the 
heart of Central America bordering to Nicaragua, El Salvador and Guatemala 
Caribbean Sea and Pacific Ocean. Honduras has a population of 8,143,564 as of July 
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2011. The first case of AIDS in Honduras was reported in 1984 [19]. In April 2012 it 
was estimated that 30,334 people were infected with HIV-1 of which 21,738 had 
developed AIDS. Approximately 47% of the HIV infections are in women and 7% in 
children under 15 years of age. This gives a prevalence of HIV-1 of around 0.8% 
[0.4–1.4%] [20]. Most Honduran HIV-1-infections have been through the 
heterosexual route and in the northern region of the country [21]. The highest 
prevalence of HIV has been observed among FSM (5%), MSM (10%), and the 
Garífuna population (4.5%) [22, 23]. Garifuna’s are descendents from black slaves 
from Africa who have maintained their culture for over two hundred years. 
Widespread poverty, poor access to health care, low level of education, low income, 
lack of employment and migrant labor have been identified as key factors influencing 
the risk of HIV in the Honduran population. Popularity of traditional myths about 
HIV is another factor associated to the risk of HIV infection in Garífuna’s [24].  
Belize is located in the north coast of Central America and has a population of 
327,719 inhabitants, in an area of 22,966 km
2
. Belize is the only Central American 
country without a coastline towards the Pacific Ocean and with English as official 
language. Belize is the country that is most severely affected by HIV/AIDS in the 
Central American region [25].  The first case of HIV infection in Belize was 
documented in 1986 [26]. The estimated adult HIV-1 prevalence was estimated to be 
around 2.3% [2.0 - 2.8%] in 2009. For year 2011, a total of 226 new infections were 
registered; a decrease of around 7% compared with year 2010. Factors such as 
multiple partners and early sexual debut are may have influenced the high prevalence 
of HIV-1 in Belize [25, 27].  
 
1.4 HIV-1 DISCOVERY  
In 1981 AIDS was first described as a clinical entity following reports by 
physicians in the United States of America about young MSM who were suffering 
opportunistic infections (i.e. Pneumocystis pneumonia) and malignancies (i.e. 
Kaposi’s sarcoma) along with immunodeficiency [28-30]. In 1983, the virus was 
isolated and identified from the lymph node of a patient by researchers at the Institute 
Pasteur in Paris (Barré-Sinoussi et al., 1983) [31].  In the meantime, several reports of 
similar clinical conditions were coming from different countries around the world 
[32, 33]. In 1984, Gallo et al demonstrated that the identified agent is the cause of 
AIDS [34]. In 1986 the isolated virus was officially named human immunodeficiency 
virus (HIV) [35].  
 
1.5 ORIGINS OF HIV-1 
Some subspecies of the chimpanzee (Pan troglodytes troglodytes and 
P.t.schweinfurthii), in West Central Africa and western gorillas (Gorilla gorilla) have 
been identified as the natural hosts of the simian immunodeficiency virus (SIV), which 
were introduced to humans as HIV-1 [36-39]. The most possible transmission route to 
human beings is through exposure to infected blood or body fluids during hunting [40].  
Phylogenetic analysis have shown that HIV-1 was introduced to humans 
through independent transmission events resulting in three genetic groups, the group 
M (major) which was the first introduced around 1910 and is responsible for the 
pandemic [41]; the group N (non M/non O) and group O (outlier), both seen in West 
Central Africa. Recently a new group, P, was discovered [42, 43]. The groups M and 
N have been clustered with SIVcpzPtt strains from Cameroonian chimpanzees [44].  
Since group O are more closely related to SIVgor strain it has been suggested that 
gorillas could be the original reservoir of this strain [38].  
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2 HIV-1 VIROLOGY  
 
2.1 HIV-1 STRUCTURE  
HIV-1 belongs to the family Retroviridae, subfamily Orthoretrovirinae and 
lentivirinae genus. Each viral particle is spherical with a diameter of 100 - 120 nm 
and contains two positive-sense single-stranded RNA molecules approximately 
10,000 nucleotide long, which are surrounded by nucleocapsid proteins [45]. The 
RNA contains genes for all HIV-1 proteins including the three major structural genes, 
gag, pol and env (Figure 1). The gag gene encodes for proteins that are necessary for 
the assembly of the viral particle. The pol gene encodes for the viral enzymes needed 
for viral replication; the reverse transcriptase (RT) which transcribes the viral RNA to 
an intermediate DNA, the integrase (IN) which allow the integration for the viral 
DNA to the host genome, and the protease (PR) which is involved in the maturation 
of the virus [46, 47]. The env gene, encodes for envelope glycoproteins gp120 and 
gp41 that are required for viral attachment and fusion to the host cells. The HIV-1 
genome also contains genes that encode two regulatory proteins (Tat, Rev) and four 
accessory proteins (Vif, Vpr, Nef, Vpu) [47]. The main function of the Tat protein is 
to facilitate the initiation and elongation of the primary transcript. The Rev protein is 
needed to transport of viral mRNA from the nucleus to cytoplasm. Vif counteracts the 
cellular antiviral defense protein APOBEC-3G which promotes the infectivity of the 
virus. Vpr, is a transactivator for host cellular genes and promotes cellular 
differentiation [48]. Nef inhibits the recognition of HIV infected cells by the host 
defense system. The Nef protein is expressed at the early phase of HIV infection 
together with Tat and Rev. Vpu, downregulates CD4 on infected cells and thereby 
enhances the release of the new viral particle [49]. The HIV-1 genes are flanked by 
two regions called non-coding long terminal repeats (LTR) that are needed for the 
transcription of the viral genome [45].  
 
 
Figure 1. Schematic Structure of HIV-1. Reprinted with permission from [46]. 
 
2.2 HIV-1 REPLICATION  
HIV begins its life cycle when it binds its gp120 surface proteins to a CD4 
receptor that is expressed on the surface of CD4+ T-lymphocytes, macrophages, brain 
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microglia, and dendritic cell (Figure 2) [50]. After the receptor binding, a 
conformational change occurs in the gp120 that allows binding to a coreceptor, CCR5 
or CXCR4, which triggers viral fusion of the viral envelope with the target cell 
membrane mediated by gp41. The viral nucleocapsid, which contains the viral 
genome, it is released into the cytoplasm of the host cell [51].  
The reverse transcription process is carried out by the RT enzyme facilitating 
the synthesis of cDNA from viral RNA. The newly formed preintegration complex 
containing the viral DNA is transported to the nucleus of the host cell. The viral 
enzyme integrase mediates integration of the viral DNA into the host chromosome 
[52]. The integrated viral DNA is called provirus and can remain in a latent stage or 
become transcriptionally active by the host machinery. The provirus serves as a 
template for production genomic RNA and messenger RNA which is translated to 
viral proteins in the cytoplasm. Then, the glycosylated env precursor proteins are 
transported to Golgi apparatus to be inserted at the cell surface [53].  
Finally the viral particle is assembled at the cellular membrane to subsequently 
be released from the cell by budding. It is estimated that the replication cycle of HIV, 
from entry to viral maturation, has duration of around 2 days. Around 10
10
 new 





Figure 2. HIV-1 life cycle. Reprinted with permission from [51]. 
 
2.3 HIV-1 DIVERSITY  
HIV-1 comprises four genetically distinct groups, M, N, O, and the recently 
identified P [42, 43, 55-59]. The HIV-1 groups have been further classified into 
subtypes, circulating recombinant forms (CRFs) and unique recombinant forms 
(URFs), based in phylogenetic analyses of genetic sequences of HIV-1. Some of the 
factors responsible for the high diversity of HIV-1 are; the lacks of proof reading of 
the RT enzyme, which leads point mutations during the reverse transcription process 
(0.1 - 0.3 mutations per genome and replication cycle) [60-62]; and recombination, 
because the RT makes template switches between the two RNA templates during 
reverse transcription. If these RNA’s are genetically distinct this leads to the 
formation of a recombinant cDNA product [63, 64]. 
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Group M, which constitutes more than 90% of current HIV infections worldwide, 
has been divided into nine subtypes, named A, B, C, D, F, G, H, J, and K [10, 65], 
and more that 50 CRFs (http:www.hiv.lanl.gov). These subtypes have different 
distribution in the world and a high degree of viral genetic variability (30% in the env 
gene) has been documented for isolates from distinct geographical a [47, 66-68]. 
Subtype B has been found predominantly in the United States and Europe and several 
Latin American countries, even if it represents less than 12% of worldwide infections, 
has been the most studied variant in terms of ARVs susceptibility [69-73]. Subtype C, 
distributed in Eastern and Southern Africa, India, and parts of China, is the most 
prevalent subtype in the HIV pandemic, and constitutes half of all known worldwide 
infections [74, 75]. The previously described subtypes E and I are not longer 
considered subtypes. The subtype E is now classified as CRFs (CRF01_ A/E) which is 
highly prevalent in South-East Asia, and subtype I as CRF04_cpx [76-78]. It has been 
suggested that the high diversity of HIV-1 has implications for transmission, 
effectiveness of ART and is one of the major challenges for the development of HIV 
vaccine [79-84].  
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3 HIV-1 INFECTION  
 
3.1 HIV-1 PATHOGENESIS  
HIV-1 infection is characterized by a deterioration of the cellular immune 
system. The immunodeficiency is characterized by progressive loss of CD4
+ 
T-cells 
that explains the development of AIDS. The risk of development onset of different 
opportunistic diseases is correlated with the degree of loss of CD4
+ 
T-cells in blood 
[85].  
Three stages have been identified in the course of HIV infection: acute phase, 
chronic phase, and AIDS. The acute phase or primary infection lasts a few weeks and 
is characterized by high viral titers in plasma (10
7
 – 108 million RNA copies/ml) and 
a transient depletion of CD4+ T cells [86, 87]. The high-level viremia can be 
accompanied by flu like symptoms as result of the host immune response [88, 89]. 
The high virus levels are associated with higher transmission rates per exposure, 
when compared with later phases of HIV [90]. During the transition to the chronic 
phase the host immune response partially controls virus replication which leads to a 
partial recovery of CD4 counts and a decrease of viral load to a level called set point, 
which is a predictor of disease progression Nevertheless viral replication is constantly 
active and the high genetic variation of the virus is facilitating emerging 
immunological escape virus [91-93]. Eventually the infection progresses to AIDS due 
to the exhaustion of the immune system which is reflected by the depletion of CD4+ 
T lymphocytes to below 200 cells/ul. At this stage the risk of multiple opportunistic 
infections or malignancies continuously increases and eventually leads to the death of 
the patient. The average time from infection to development of AIDS is around 10 
years without treatment [91, 94].   
   
3.2 IMMUNE ACTIVATION IN HIV-1 INFECTION  
In the first stages of HIV infection, a profound destruction of CD4+ T-cells 
occurs in mucosal tissues of the gastrointestinal tract [95]. As these cells are not 
completely replaced, the host remains deficient in memory cells, triggering a lack of 
control of the microorganisms, which contributes to a more generalized activation of 
the immune system. Followed the dramatic depletion of CD4+ T cells, the altered 
integrity of the mucosa cause the leakage of microbial products into the circulation, 
process known as microbial translocation.  This process is evidenced by increased 
levels of circulating lipopolysaccharides (LPS) in plasma (the major constituent of the 
cell wall in Gram-negative bacteria) [96, 97].   
LPS is a potent immune-stimulator product that activates monocytes and 
macrophages, which are the major reservoirs of HIV-1 during all stages of infection 
[98]. Some studies have associated the levels of LPS in plasma to increased immune 
activation [99-101] which has been proposed as an independent marker of the disease 
progression [97, 102]. 
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4 ANTIRETROVIRAL THERAPY  
    
Antiretroviral therapy (ART) consists in the use of pharmacologic agents that 
have specific inhibitory effects on HIV replication cycle. The primary goal of ART is 
the suppression of viral replication, to promote restoration and/or preservation of 
immune functions in order to reduce HIV-related morbidity and mortality.  
Antiretroviral drugs belong to six classes of drugs which target different steps in 
the viral life cycle (Figure 3). (1) The nucleoside and nucleotide reverse transcriptase 
inhibitors (NRTIs) are analogues of the naturally occurring building blocks needed to 
synthesize the viral DNA, and when incorporated into the growing viral DNA chain 
they cause chain termination [103]. (2) The non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) interfere with the reverse transcription by directly binding to the 
enzyme and thereby block the polymerase activity. (3) The protease inhibitors (PIs) 
inhibit the viral maturation process by binding to the protease enzyme prohibiting 
cleavage of the viral precursor protein resulting in lack of functional virion formation 
[104]. (4) The integrase inhibitors target the HIV enzyme integrase, which is 
responsible for the integration of viral genetic material into the human host cell DNA, a 
crucial step in the replication cycle of HIV-1 [105]. Viral entry can be blocked by (5) 
fusion inhibitors and (6) CCR5 co-receptor antagonists that interfere early in the 
replication cycle with the receptor-mediated entry of the virus into a cell by a blocking 
process of gp41 domain inhibiting the conformational change of gp41 that is necessary 
for fusion of virions to the host cell, or blocking the CCR5 co-receptor and thereby 
inhibiting it interaction with viral surface protein gp120 necessary for viral entry into 




Figure 3. Antiretroviral drug targets for HIV-1 viral cycle steps. Reprinted with 
permission from [109].  
 
Currently, more than 25 antiretroviral drugs are approved by Food and Drug 
Administration (FDA-USA) (Table 1) for use in HIV-infected adults and adolescents 
and 23 have been approved for pediatric treatment; as well multi-class drug 
combinations. Significant advances have been made through the years to improve the 
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ART regimens which as improved the quality of life for infected adults and children. 
The most important advance was the introduction in 1996 of combination 
antiretroviral therapy (cART), which made it possible to achieve to a maximal and 
durable virologic suppression. In recent years the main advances has been in terms of 
reducing the toxicity of the therapy. Nonetheless, the scaling up access in developing 
countries is still a challenge, mainly in terms of cost. Several important factors have 
to be considered for the administration of ART including; adverse effects, long-term 
drug toxicities, complexity of use, adherence and development of HIV-1 drug 
resistance [110].  
 
Table 1. Antiretroviral drugs approved by FDA for adult treatment 
infection in adults and pediatric infection. 
Class of drug Antiretroviral drugs 
for use in Adults 
Abbreviation    Year of  
  approval 
 
NRTIs Zidovudine AZT (ZDV)* 1987 
 Didanosine ddI* 1991 
 Zalcitabine  ddC* 1992 
 Stavudine d4T* 1994 
 Lamivudine 3TC* 1995 
 Abacavir ABC* 1998 
 Tenofovir  TDF* 2001 
 Emtricitabine FTC* 2003 
 
NNRTIs Nevirapine NVP* 1996 
 Delavirdine DLV* 1997 
 Efavirenz EFV* 1998 
 Amprenavir  APV 1999 
 Etravirine ETR 2008 
 Rilpivirine - 2011 
 
PIs Saquinavir  SQV* 1995 
 Indinavir IDV 1996 
 Ritonavir RTV* 1996 
 Nelfinavir NFV* 1997 
 Amprenavir  APV* 1999 
 Lopinavir  LPV* 2000 
 Fosamprenavir  fAPV* 2003 
 Atazanavir  ATV* 2003 
 Tipranavir TPV* 2005 
 Darunavir - 2006 
 
Fusion Inhibitors Enfuvirtide T-20* 2003 
 
Entry Inhibitors  Maraviroc MVC* 2007 
 
Integrase inhibitors Raltegravir RAL* 2007 
 
*Antiretroviral drugs used in children 
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5 PREVENTION STRATEGIES OF MOTHER-TO-CHILD 
TRANSMISSION OF HIV-1 
 
5.1 MOTHER-TO-CHILD TRANSMISSION OF HIV-1 
Mother-to-child transmission of HIV-1 (MTCT) is responsible of more than 
90% of pediatric infections worldwide [111]. Children can be infected during 
pregnancy, labor, delivery, and breastfeeding [112].  
Without any type of preventive measure, there is a risk of transmission of 
around 15-30% in non-breastfeeding population. A majority (65%) of these 
transmissions occur during labor, whereas 35% in utero. An additional risk of 5-20% 
exists when the child is breastfeed, for an overall transmission rate of 20-45% [113, 
114]. Several factors may influence the MTCT such as high maternal viral load levels 
(mainly in the last months of pregnancy and/or during labor) [115], amount of virus 
in genital secretions and in the cervix site; low levels of CD4+ T cell count (≤200 
CD4+ cell/mm
3
) [116, 117]. Another important factor associated to vertical 
transmission is the duration of membrane rupture, especially if longer than 4 hours 
[118-120]. Other factors that are associated with the risk of MTCT are co-infections 
with hepatitis C, as well as breast diseases abscesses and mastitis [121-123]. Viral 
factors such as certains subtypes and types of co-receptor use have also been 
associated with an increased risk of vertical transmission [124-127]. 
The availability of prevention strategies to avoid MTCT of HIV-1  have resulted 
in a dramatic decline of the infections in this population around the world. Several 
studies have demonstrated that the risk of MTCT can be substantially reduced if 
adequate preventive measures are provided. Preventive MTCT interventions include: 
HIV-1 testing, Caesarian section as mode of delivery before labor and before 
membrane rupture of, abstaining of maternal breast feeding, and antiretroviral 
prophylaxis for the mother and the child [117, 128].   
 
5.2 HIV-1 TESTING 
One of the key factors involved in the prevention of MTCT is the identification 
of an ongoing HIV-1 infection in the pregnant women in good time before delivery. 
The HIV-1 diagnosis enables infected women and infants to benefit from a timely  
intervention to prevent MTCT. Over the years, important advances has been done in the 
diagnosis of HIV-1 infections. At the present time, the fourth generation enzyme-linked 
immunosorbent assays (ELISA) and enhanced rapid tests have been used for screening 
of adult population including pregnant women [129-131]. Reactive ELISA results are 
traditionally confirmed by an immunoblot  [103], but other testing algorithms based on 
only ELISAs and rapid tests have proven accurate and cost-effective. Such algorithms 
have been endorsed by the WHO for use in resource-limited settings [132]. In 
Honduras, the National guidelines for diagnosis of HIV-1 infection in pregnant women 
recommends the use of two rapid tests (Determine HIV-1/2 rapid test and OraQuick 
advance rapid antibody test HIV-1/2).  
In addition to the serological tests molecular methods, i.e. polymerase chain 
reaction (PCR), are available for diagnosis of HIV-1-infection. However, these 
methods are only used for specific issues such as indeterminate results or discordant 
results between screening and confirmatory results in adults [103]. 
In children born by HIV-1 infected women, maternal IgG antibodies are 
transplacentally transferred from week 32 of pregnancy and may remain detectable 
until the age of 18 months. Therefore antibody detection is generally only used to 
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diagnose HIV-1 infection in children older than 18 months [133, 134]. HIV-1 
infection in younger infants (<18 months of age) is best diagnosed by two separate 
positive results obtained by PCR detection of HIV-DNA in peripheral blood 
mononuclear cells and/or HIV-RNA in plasma [103, 135]. Several studies have 
reported a variation in the sensitivity of PCR testing depending on the infant’s age and 
the type of nucleic acid detected, ranging from 25% to 50% within the first three weeks 
of age to 96.2% by four to six weeks of age and reaching 100% after seven weeks of 
age [136, 137]. HIV-RNA assays have shown to be slightly more sensitive than HIV-1 
DNA assays among young infants. Nevertheless, because of the reduced amount of 
detectable HIV-1 RNA in plasma during ART there are concerns about performing 
RNA assays for diagnosis in infants receiving ART [132, 138]. The use of molecular 
techniques to detect HIV-1 in infants has also enabled determination of the time of 
acquisition. If HIV-DNA/RNA is detected within 48 hours of birth it is assumed that 
the infection was acquired in utero, and when detectable first after 7 to 90 days it is 
considered as intrapartum infection [139]. 
Currently, the use of DNA-PCR in resource-constrained settings has become a 
feasible and powerful tool for HIV-1 detection in infants. Importantly, since the 
introduction and use of filter paper for sample collection it has been possible to 
overcome the logistical obstacles in the sample collection such as amount of sample, 
transportation, and storage [138, 140].  
 
5.3 CAESAREAN SECTION 
Cesarean section before labor and rupture of membranes, also called elective 
Caesarean section, is a good strategy to reduce the risk of MTCT by approximately 
50% [141]. Several studies have found that elective Caesarean section is an useful 
intervention among women whom are not under antiretroviral prophylaxis, or only 
receiving sub-optimal antiretroviral prophylaxis, and for women who have viral load 
levels greater than 1000 copies/ml [142-144]. In studies done in women who have 
viral load levels below 1000 copies/ml, no difference have been found in transmission 
prevalence among vaginal delivery and elective Caesarean section [117, 145, 146]. 
As some studies have observed an increased risk for postpartum complications among 
women who undergo Caesarean as compared to vaginal delivery it is important to 
consider maternal morbidity associated to elective Caesarean section and the 
risk/benefit ratio when using this prevention strategy [142, 147, 148]. In several, 
resource-rich countries, including Sweden, Caesarean section is now optional, and not 
always recommended, for pregnant women with successful cART in the last weeks of 
pregnancy [149]. 
 
5.4 BREASTFEEDING  
After the first report of transmission of HIV-1 through breastfeeding in 1985, it 
has been widely recommended to avoid maternal feeding for children who are born 
from HIV-1 infected women [150]. However, in resource-constrained regions, where 
alternative feeding options are not always feasible, breastfeeding is still 
recommended [151-153]. As the transmission of HIV-1 by breastfeeding in poor 
settings still occur [154], there are some preventive interventions that have been 
designed such as the complete avoidance or decreasing the duration of exposure to 
breastfeeding, decreasing maternal infectivity using chemical or heat treatment to 
diminish the viral load in breast milk , and use of antiretroviral prophylaxis at time of 
breastfeeding in women and children [155-158]. Several studies done in sub-Saharan 
Africa in the context of early cessation of breastfeeding found significant morbidity 
associated with this type of intervention [159]. About heat treatment of breast milk, it 
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has been found to lower viral load in the milk without obvious harmful effects, but 
data are limited [160-163]. Data from several studies have shown that maternal 
antiretroviral prophylaxis during breastfeeding decreases the risk of MTCT [159]. 
 
5.5 ANTIRETROVIRAL TREATMENT PROPHYLAXIS 
Treatment and prophylaxis with antiretroviral drugs are the most effective 
intervention to prevent MTCT and therefore forms the basis of all recommended 
preventive strategies. In women, antiretroviral prophylaxis reduces viral load in 
plasma, vaginal secretions and breast milk. The antiretrovirals also cross the placenta 
and provide the fetus with pre-exposure prophylaxis against transmission of virus in the 
maternal genital tract and blood at time of delivery [103]. AZT is the antiretroviral drug 
that has been most widely used in for MTCT prevention, partly because it was the first 
available antiretroviral drug and also the first drug with demonstrated efficacy in the 
prevention of perinatal transmission of HIV-1. Thus, the Pediatric AIDS Clinical Trials 
Group (PACTG 076) in 1994, reported that AZT administered to the pregnant woman 
between 14 to 34 weeks of pregnancy and to the infant for 6 weeks after delivery 
reduced the risk of perinatal transmission from 25.5 to 8.3% [164]. Based on these data 
several intervention strategies using AZT were developed [165]. One was 
implemented in PETRA trial performed in Africa with a combination of AZT and 
3TC started at 36 weeks of pregnancy, intrapartum, and during one week postpartum 
to the woman and infant, which reduced transmission by approximately 50% 
compared with AZT alone [166]. Currently AZT is the antiretroviral drug most 
extensively used in pregnancy and remains an important component of multiple drug 
regimens using other NRTIs, NNRTIs and PIs.  
In 1999, another antiretroviral drug, NVP, which is a potent NNRTI, was used in 
a single-dose (sdNVP) in the HIVNET 012 trial conducted in Uganda.  NVP was 
administered during labor to women and postpartum to infants and showed a reduction 
of transmission by nearly 50% compared with intra- and postpartum AZT [167]. 
Additionally, high effectiveness (72% reduction compared to AZT) was reported by a 
combination of AZT and sdNVP in the ANRS 1201/1202 DITRAME PLUS A study 
[168]. However, even if sdNVP is a potent intervention against MTCT it no longer 
recommended, because it is associated with rapid development of resistance to NVP 
[169]. Nevertheless, sdNVP is still in used in resource constrained settings if other 
options are not available.  
In more recent years there have been important progress in MTCT prevention by 
implementation of cART, which have been highly successful in preventing MTCT in 
developed countries [170]. When successful, cART gives prolonged suppression of 
viral replication, plasma viral levels below the detection limit (<50 copies/mL), and 
thereby minimizes the risk of development of drug resistance. Thus, preventive MTCT 
studies in the US as well as Europe have documented reductions of transmission rates 
to below to 2% with the use of cART [141, 171, 172].  The World Health Organization 
(WHO) in its 2010 guidelines for MTCT prevention recommends the initiation of 
cART prophylaxis as early as 14 weeks of pregnancy. Recommended regimens in this 
current guideline include AZT + 3TC in combination with one of these drugs:  
ritonavir boosted lopinavir (LPV/r), ABC or EFV.  It is recommended that EFV 
should be replaced by NVP if the pregnant woman is in the first trimester of gestation 
[173]. For our project it is also relevant to mention that the 2006 WHO guidelines 
recommended the use of AZT from 28 weeks of pregnancy plus intrapartum sdNVP + 
AZT + 3TC; and AZT + 3TC for 7 days postpartum [174]. The prevention of MTCT 
by the use of antiretroviral drugs also includes the prophylaxis for neonates, by 
administration of antiretrovirals after birth. The most common antiretroviral drug used 
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for HIV-exposed infants has been AZT for a period of four to six weeks [173]. Other 
antiretroviral drugs have been used in combination with AZT for infant prophylaxis, 
such as NVP, and 3TC [134, 175]. The use of additional antiretroviral drugs for infant 
prophylaxis mainly depends on maternal history of antiretroviral drug exposure, HIV-
RNA levels at or near delivery, premature rupture of membranes, documented 
maternal resistance to antiretroviral drugs [103, 149]. 
The use of strategies to avoid MTCT in Honduras began during year 2001, when 
a pilot project to prevent MTCT based on mono-therapy with AZT or NVP was 
initiated. In 2003, after considering the prevention of MTCT as a national priority, “The 
National Program for MTCT Prevention” was implemented to provide better 
prevention of MTCT throughout the country. Currently, and in relative accordance with 
WHO guidelines, cART including AZT, 3TC and NVP or more recently AZT, 3TC 
and LPV/r are used for MTCT prevention in Honduras from 28 weeks of pregnancy 
[176]. However, currently it is difficult to implement these guidelines for every 
pregnant woman in Honduras.  
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6 ANTIRETROVIRAL RESISTANCE   
 
6.1  GENERAL ASPECTS OF ANTIRETROVIRAL RESISTANCE  
HIV-1 resistance to antiretroviral drugs is a major cause and consequence of 
treatment failure among patients receiving ART and is therefore considered a serious 
clinical problem worldwide.  
HIV-1 drug resistance is defined as any change in the nucleotide sequence of the 
virus that improves viral replication in the presence of an antiretroviral drug [103]. As 
previously mentioned in section 4, the goal of ART is to inhibit completely viral 
replication in vivo and sustain the effect for as long as possible. However, resistant viral 
population can evolve in the presence of antiretroviral drugs, especially if they are 
given in suboptimal concentrations or combinations [177].  
Some viral factors promote the development of resistant variants. These factors 
include: 1) The high turnover of HIV-1, producing around ten million viral particles per 
day; 2) The high error rate of the HIV-1 RT that results in production of new viral 
strains with mutations [178, 179]. Other factors that contribute to development of 
resistance are: 1) Poor adherence to antiretroviral drugs; 2) The level of genetic barrier 
of the drugs; 3) Potency of the regimen used [180, 181]. 
There is considerable knowledge about which mutations in the HIV-1 genome 
mediate resistance to three main drug classes, NRTIs, NNRTIs and PIs [182-184]. The 
most common mutation to NRTIs is M184V, which emerges rapidly in patients 
receiving non-suppressive therapy with 3TC or FTC. M184V by itself confers high-
level resistance to both antiretroviral drugs. Thymidine analog mutations (TAMs), 
which are mainly involved in resistance to AZT and d4T, are also common NRTI 
resistance mutations. For NNRTIs, the most clinically important mutation is K103N, 
which causes high-level cross resistance to all NNRTIs [182]. In the case of PIs, 
resistance develops more slowly because high level resistance requires accumulation of 
several mutations [180]. Resistance mutations to T-20, the only FDA-approved HIV 
fusion inhibitor, and to RAL, the first approved integrase inhibitor has also been 
documented [185, 186].  
 
6.2 TRANSMITTED ANTIRETROVIRAL RESISTANCE 
The introduction of ART has greatly improvement the morbidity and mortality 
in HIV infected patients, however, the wide use of ART has led to an increase 
proportion of drug resistance among patients on therapy. Patients with drug resistant 
HIV sometimes transmit the infection to others. Such transmitted drug resistance 
(TDR) is a potential threat to the success of ART [187]. 
Transmission of drug-resistant viruses occurs irrespective of the route of 
infection and it prevalence may vary from 1 to 25% in cohorts from different 
geographical areas and risk groups [188]. Currently the presence of one or more of 93 
mutations (34 NRTI mutations, 19 to NNRTIs and 40 PI) associated with drug 
resistance are considered as evidence of TDR [189].  
Several studies have shown that some transmitted resistant strains can gradually 
revert to wild-type virus due to fitness cost of certain resistance mutations. Other 
mutations, with lower fitness costs, may be maintained for at least 1–2 years after 
transmission and also may persist as minority variants [190, 191]. Such minority 
variants may impact on responses to ART. For example, the NRTI mutation M184V, 
which causes resistance to 3TC and FTC, reduces fitness and therefore rapidly reverts 
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after transmission. In contrast, the NNRTI resistance mutations K103N and Y181C 
have low impact in viral fitness, and therefore revert more slowly [192]. 
Many studies have reported on TDR in developed countries [193]. However, 
reports on TDR in resource limited settings are scarcer. This is especially true for 
TDR among pregnant HIV-1 infected women and in Central America. 
 
6.3 RESISTANCE TESTING 
International HIV treatment guidelines recommend that testing of antiretroviral 
drug resistance should be part of the management and care of people living with HIV.  
Thus, it has been demonstrated that resistance testing help clinicians to identify which 
could be the most appropriate antiretroviral regimen for each individual [194-196]. 
There are two main methods to determine the HIV resistance to antiretroviral drugs: 1) 
Phenotypic tests and 2) Genotypic tests. In phenotypic resistance tests a patient HIV-1 
isolate or recombinant virus with a pol gene derived from the virus of the patient is 
cultured in presence of dilutions on an inhibitory drug. This test determines the drug 
concentration that reduces virus replication by 50% (IC50), or 90% (IC90). Then the 
result is compared with the IC50 or IC90 obtained for a wild-type virus. The genotypic 
resistance test is based on the analysis of HIV sequences in order to determine the 
presence of mutations that are known to be associated with reduced sensitivity to 
antiretrovirals [197, 198]. The interpretation of genotypic test is done by the use of 
bioinformatics algorithms that are designed to estimate the clinical utility of the 
antiretroviral drugs based on which resistance mutations are present in the viral strain. 
The rule-based algorithms ANRS, Stanford HIVdb, and Rega algorithms are the most 
commonly used [183, 184, 199]. The genotypic resistance test is the most used method 
to determine the presence of resistance in clinical settings because is considered 
simpler, faster and less expensive than phenotypic resistance test [184, 200]. 
 
6.4 ANTIRETROVIRAL RESISTANCE DURING PREGNANCY 
The use of antiretroviral prophylaxis in HIV-1 infected pregnant women has 
resulted in significant reduction of MTCT [128]. The development of antiretroviral 
drug resistance in pregnant women is a concern, since it may diminish the efficacy of 
ART to prevent MTCT and also may limit future options for maternal treatment [201, 
202]. When maternal resistant virus is transmitted to the child, treatment options in the 
infected child may also be limited [203, 204].  
Like with other use ART, mono-therapy and dual-therapy in pregnant women is 
more prone to development of ART. This is especially true if drugs with low genetic 
barrier, like 3TC and NVP, are used [175, 180, 181]. Regarding to NVP, is well known 
that its’ long half-life increases the risk of development of resistance following 
cessation of therapy in women who received sdNVP [205, 206]. Thus, sdNVP to 
pregnant women is associated with rapid development of the K103N mutation. In the 
HIVNET 012 study NVP resistance was detected in 20% of women who only 
received a single intrapartum dose. Reversion to wild type virus was seen among 
these women [207]. Nevertheless, high risk of re-emergence of NVP resistance exists 
if NVP-based therapy is resumed. The risk of resistance to NVP after administration of 
two doses in women is higher than the observed after a sdNVP [208]. Also resistance 
mutations can also arise in pregnant   women after HAART-prophylaxis [202, 209].  
Resistance to NRTIs and NNRTIs can frequently occur in infants that become 
infected despite the NVP-based interventions. In the KiBS study done in Kenya, 67% 
of infants who became infected despite maternal triple prophylaxis had drug 
resistance, some to both NNRTIs and NRTIs [210]. The SWEN study reported that 
92% of infants who became infected had resistance to NNRTIs [211].  
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With the widespread use of antiretrovirals, TDR is also considered a concern in 
pregnant women population. Surveillance studies have registered prevalence of TDR 
higher than 7% in treatment-naïve pregnant women [212-214]. As was previously 
mentioned the use of antiretrovirals in Honduras for MTCT prevention started around 
twelve years ago, and today cART is provided to most women who receive 
antiretroviral prophylaxis against MTCT. However, all pregnant women are not 
screened for HIV-1-infection and consequently do not benefit from antiretroviral 
prophylaxis against MTCT. Resistance tests are not routinely used in Honduras and 
consequently there is very limited information about antiretroviral drug resistance in 




The overall aim of this project was to investigate different aspects of MTCT of 
HIV-1 in two Central American countries, Honduras and Belize.   
 
The specific aims were:  
 
Paper I:  To investigate the prevalence of antiretroviral drug resistance in HIV-1-
infected infants from Honduras and Belize born 2001 to 2004.   
 
Paper II:     To investigate antiretroviral drug resistance, microbial translocation, and 
incidence of HIV-1 transmission, following pregnant Honduran women 
who received antiretroviral prophylaxis to prevent MTCT. 
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8 STUDY POPULATION AND METHODS   
  
8.1 STUDY POPULATION AND SAMPLE COLLECTION 
 
Paper I  
Paper I is based on a retrospective cohort study, which investigated the 
prevalence of drug resistance in HIV-1-infected Honduran and Belizean infants before 
cART was recommended for prevention of MTCT in the region. The study was done in 
collaboration with the National HIV/AIDS Program from Honduras and the Maternal 
and Child Health Center from the Belizean Ministry of Health. The study included 95 
HIV-1 infected infants born between years 2001 and 2004 in Honduras (n=70) and 
Belize (n=25). Dried blood spots (DBS) were collected from the infants between 2 
weeks to 20 months after delivery. Genotypic resistance testing was successful in 66 
(70%) of the DBS samples. The lack of amplification in remaining samples could 
potentially be due to DNA degradation during DBS storage.  
 
Paper II 
Paper II is based on a prospective cohort study of HIV-1-infected pregnant 
Honduran women who received cART as prophylaxis against MTCT. We assessed the 
risk of transmission to the infants as well as antiretroviral drug resistance and microbial 
translocation in the mothers. The study was done in collaboration with the Honduran 
Ministry of Health. A total of 50 Honduran HIV-1-infected pregnant women and their 
infants were recruited to the study following informed consent. Sample collection was 
done between November 2007 and September 2010.  Twenty-nine of the women were 
treatment-naïve and 21 were treatment-experienced. The treatment-naïve women were 
identified as HIV-1-infected when HIV testing was done as part of the prenatal control, 
while the treatment-experienced women already were patients at the participating 
health centers when they became pregnant. 
Sample collections (Figure 4) were done at three major health centers in the 
capital city Tegucigalpa: Centro de Salud Alonso Suazo, Hospital Escuela, and Instituto 
Hondureño de Seguridad Social (IHSS) and two major health centers in San Pedro Sula 
(SPS): Hospital Mario Catarino Rivas and IHSS-SPS. Plasma samples were collected 
from the HIV-infected women at two time points: at 20 - 34 weeks of pregnancy 
(baseline sample) and 3 - 10 days after delivery (follow-up sample). For treatment-
naïve women, baseline samples were collected following diagnosis and before the start 
of antiretroviral prophylaxis. The follow-up samples were collected a few days after 
delivery, after they stopped antiretroviral prophylaxis. For treatment-experienced 
women baseline and follow-up samples were obtained during ongoing ART. From the 
infants DBS were collected at two time points, at 72 hours and 1 month of age, to 
evaluate their HIV status by HIV-1 DNA-PCR. 
An additional objective for paper II was to evaluate microbial translocation 
during and after pregnancy, by measuring lipopolysaccharide (LPS) in plasma. 
Microbial translocation has been suggested to drive inflammatory events in HIV-1 
infected individuals, and the plasma levels of LPS to be associated with increased 
levels of immune activation.  The levels of LPS were measured at the two time points 
in samples from 20 HIV-1 infected women who were selected randomly from the study 
cohort. The LPS levels in the study women were compared with LPS levels in 95 HIV 







Figure 4. Sample collection for resistance-study among pregnant women and their 
infants during years 2007 to 2010 (Paper II). MS: sample from the mother; BS: sample 
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8.2 LABORATORY METHODOLOGIES 
 
The Laboratory methodologies used for Paper I and II are summarized in Table 2.  
 
Table 2. Laboratory methods used for studies done in mother-child populations in 
Paper I and Paper II 
Laboratory methodology Method Paper 
Sample collection from 
infants 
Dried blood spots (DBS). Filter paper from Flinders 
Technology Associates (FTA cards; Whatman international 
Ltd. Maidstone, England) [140]. 
I-II 
Sample collection from 
women 
Plasma-preparation tubes (PPT) (Becton Dickinson, USA) 
Storage at -80°C.  
I 
DNA extraction from DBS 
samples 
Whatman FTA Purification reagent (Whatman International 
Ltd. UK) and Tris-EDTA buffer (SIGMA CHEMICAL CO., 
St. Louis, USA). 
I-II 
RNA extraction  QIAmp RNA mini kit (Qiagen, Hilden, Germany). I 
Determination of HIV 
status for infants
 
In-house nested HIV-1 DNA PCR targeting a region of the 
pol gene (amino acids 17
 
to 237 of the RT (Beck et al 






Sequencing of HIV-1 pol gene (amino acids 1–99 in the 
protease and 1–253 in the RT) with a published in-house 
method (Lindstrom and Albert, 2003 protocol), using the 
ABI Prism 3100 Genetic Analyzer (Applied Biosystems, 
Stockholm, Sweden) using Big Dye terminator sequencing 




Sequencher software (Gene Codes Corporation, Ann Arbor, 
MI, USA)/BioEdit version 7.0.9.0 [216]. 
I-II 
Identification of resistance 
associated mutations in 
treatment-naïve patients  
Calibrated Population Resistance Tool (CPR) (version 5.0 
beta updated 01/26/10) for surveillance drug resistance 
mutations (SDRM) available at the Stanford University HIV 
Drug Resistance Database 
(http://cpr.stanford.edu/cpr/servlet/CPR) [217]. 
I-II 
Identification of resistance 
associated mutations in 
treatment-experienced 
patients 
Agence Nationale de Reserches Sur le SIDA (ANRS) 
algorithm (July 2009, version 18) [218]. 
II 
Phylogenetic analysis   Neighbor-joining phylogenetic trees using the MEGA 4 
software[219]. 
I-II 
Quantification of plasma 
HIV-1 RNA  
Amplicor HIV-1 monitor system (Roche, Rotkreuz, 
Switzerland).  
II 
Measurements of levels of 
gram-negative bacterial 
endotoxin (LPS) in plasma 
Limulus amebocyte lysate assay LAL (Lonza Group, Ltd. 




8.3 STATISTICAL ANALYSIS  
Statistical analyses were processed with EpiInfo software 6.4 (Center for Disease 
Control and Prevention, CDC), GraphPad Prism 5.0 software and InfoStat version 1.1. 
  
8.4 ETHICAL CONSIDERATIONS 
Studies performed in Paper I and Paper II, were conducted with the approval of 
Ethics Committees in Honduras and Sweden (Dnr. 21/ 2009).  
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9 RESULTS AND DISCUSSION 
 
9.1 DRUG RESISTANCE IN PREGNANT HIV-1 WOMEN IN HONDURAS 
AND THEIR CHILDREN  
The use of ART to prevent MTCT significantly improves the life for HIV-
infected mothers and their children. However, if the pregnant women are already 
infected with HIV-1 resistant strains, or if such resistant strains emerge during 
prophylaxis, this can cause treatment problems in the woman and the offspring if 
transmitted. Thus, antiretroviral drug resistance in pregnant HIV-1-infected women is a 
public health concern.  
Prevention of MTCT in Honduras, started during year 2001 by the use of mono-
therapy (AZT or NVP) within a pilot program coordinated by the Ministry of Health 
and UNICEF. The pilot program included only health centers in the two major cities in 
Honduras, the capital Tegucigalpa and the main industrial center San Pedro Sula. The 
program was gradually expanded and at the end of 2005 covered 21.4% of the health 
units in the National Health System. In 2005, 267 pregnant women were diagnosed 
with an HIV-1-infection, which corresponded to a HIV-1 prevalence of 0.57% in this 
population. Antiretroviral prophylaxis with mono-therapy and dual-therapy was given 
to 74% of the HIV-1 infected women [220]. In recent years the National Program has 
scaled up access to provide better national coverage as well as more efficacious 
antiretroviral prophylaxis based on cART.  
Currently the prevalence of HIV in pregnant women in Honduras is around 0.2% 
[20]. When this project was initiated in 2005, HIV-1 resistance testing was not 
available in Honduras and consequently there was a lack of information about HIV 
resistance in the mother-child population. However, it was recognized that HIV drug 
resistance is one of the major obstacle for effective treatment and prevention of MTCT. 
This lead to the initiation of the project “Molecular Epidemiology of HIV-1 in Central 
American region and Drug Resistant in Honduras”; a scientific cooperation between 
National Autonomous University of Honduras and the Swedish Institute for Infectious 
Disease Control and the Karolinska Institutet in Sweden funded by SIDA/SAREC. One 
of the aims with the project was to assess the prevalence of antiretroviral drug 
resistance in Honduran HIV-1-infected pregnant women and its potential transmission 
to their infants.  
The first goal of the MTCT study (Paper I), was to retrospectively evaluate the 
prevalence of drug resistance in samples from HIV positive Honduran infants born 
during 2001-2004, i.e. at time when the National Program for MTCT Prevention 
started and antiretroviral prophylaxis still was based on mono- or dual therapy. In 
addition, collaboration with Ministry of Health in Belize was established. Belize has 
among the highest frequency of HIV-1 infected individuals in the Central American 
region (2.3%), but there was very limited information about prevalence of HIV-1 
drug resistance. The MTCT program in Belize formally began in 2002 with the 
exclusive use of sdNVP [25-27].  
The second goal of the MTCT study (Paper II) was to evaluate certain aspects 
of the current MTCT prevention program (e.g. antiretroviral prophylaxis) in 
Honduras. This included: 1) The frequency of transmission of HIV-1 from mother to 
child; 2) The effect on maternal virus levels; 3) The prevalence and development of 
drug resistance in pregnant women; and 4) Changes during pregnancy in LPS levels, 
a marker of microbial translocation associated with immune activation.  
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9.1.1 Antiretroviral drug resistance in infants from Honduras and Belize 
(Paper I) 
The 66 infants analyzed in this study represented approximately 70% of all 
infants diagnosed in Honduras and 52% of infants diagnosed in Belize during 2001 to 
2004 (Table 3). Only 18% of the Honduran mothers, but 72% of the Belizean 
mothers, reported that they had received antiretroviral prophylaxis during pregnancy.  
 
Table 3. Demographics and characteristics of the HIV-1 infected infants 
Demographics Honduras Belize 
HIV-1 infected infants 55 11 
 
Age in weeks [median (range)]  24 (2 - 80) 16 (4 - 44) 
 
Infants born to mothers receiving 






Most common type of delivery [n (%)] 
Vaginal delivery  








Most common type of feeding [n(%)] 
Formula feeding  









Mutations associated with drug resistance were found in 15% of the infants, with 
13% (7/55) resistance in the Honduran infants and 27% (3/11) resistance in the 
Belizean infants. Among Honduran infants with antiretroviral drug resistance, the age 
range was between 1 to 13 months. For the Honduran and Belizean babies with 
resistance, 43% and 67% of their mothers had received prophylactic treatment during 
pregnancy, respectively. 
In Honduran infants we documented antiretroviral drug resistance to all three 
major drug classes (NNRTIs, NRTIs and PIs). Four infants had NNRTI resistance 
mutations. The dominance of resistance to NNRTIs is in accordance with other studies 
[221] and is likely related to the wide use of NNRTI drugs in Honduras, especially 
NVP that was one of the first drugs available. Furthermore, it has been well established 
that HIV has the ability to develop NNRTI resistance mutations during mono-therapy 
due to the low genetic barrier [180]. The long half-life of NVP, which can persist in 
low levels for more that 3 weeks, also promotes selection of resistance mutations [205, 
206]. Similarly, due to the exclusive use of NVP as prophylaxis in pregnant women in 
Belize during the study period 100% of the resistance mutations found in the Belizean 
infants were associated with resistance to NNRTIs. In Belize, the use of monotherapy 
to prevent MTCT continued until 2006 when cART was introduced [25]. For the 
infants all resistance is considered to be TDR since none of the infants received 
treatment.  
Five of the 10 babies infected with antiretroviral drug resistant HIV-1 were born 
from women who were not treated during pregnancy, and who reported to be 
antiretroviral drug naïve (4/7 from Honduras and 1/3 from Belize). This indicates that 
the women themselves had been infected with resistant virus, which was onwards 
transmitted to the infants. However, it is difficult to completely rule out unreported use 
of ART. Several different NNRTI mutations were observed among the infants. The 
Y181C mutation was the most frequently found (n=3), but also K103N and V106AV 
were observed. All three mutations confer high-level resistance to NVP and EFV and 
have been reported in HIV-1 infected infants also by others [177, 222, 223]. K103N, 
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which is the most important NNRTI resistance mutation [224], is commonly found in 
HIV-1-infected pregnant women who have received NVP [169].  
The phylogenetic analysis shows that 100% of Honduran and 82% of Belizean 
infants harbored HIV-1 subtype B viral strains. Two infants (18%) from Belize were 
infected with subtype C, however none of them showed resistance to antiretroviral 
drugs.  
Despite increased access to ART in the Central American countries, there are 
very few studies investigating the impact of treatment on the level of antiretroviral drug 
resistance in the region [225-229]. This study (Paper I) was the first conducted to 
determine the prevalence of MTCT HIV drug resistance in HIV-1 infected infants in 
Honduras and Belize. The prevalence of TDR found in Honduran infants in this study 
is higher than the prevalence found in previous studies in adults [225, 226]. Although 
the sample size was relatively small in both this and earlier studies, it implies that drug 
resistance is prevalent and needs to be considered already when starting first-line 
therapy. The study clearly shows that drug resistance and transmitted drug resistance 
was an important problem among Honduran and Belizean HIV-1-infected pregnant 
women and their infants when mono-therapy was the only available option to prevent 
MTCT.  
 
9.1.2 Impact of antiretroviral prophylaxis in HIV-1-infected pregnant 
Honduran women (Paper II) 
The primary objective of this study was to study the prevalence (baseline) and 
potential development (follow-up) of drug resistance in HIV-1-infected Honduran 
women receiving antiretroviral prophylaxis during pregnancy (Table 4). The second 
aim was to evaluate the risk for MTCT. Thirdly, to investigate if pregnancy, viral load, 
and drug resistance associated mutations had an impact on the level of immune 
activation by measuring LPS in plasma.   
 





Patients [n (%)] 29 21 
 
Weeks on prophylaxis [median (range)] 
 
6 (3-20) - 
 
Years on ART [median (range)] - 3 (3*-9) 
 
Most common prophylaxis given [n (%)] 
NRTI/PI (AZT + 3TC + LPV/r)  









Plasma virus level at baseline, copies/ml 
[median (range)] 
 
1,200 (<50 - >100,000) 
 
500 ((<50 - >100,000 
 
Plasma virus level at follow-up, copies/ml 
[median (range)] 
 
<50 (<50 - >100,000) 
 
<50 (<50 - 44,600) 
 
*Range in Months.  
 
The prevalence of antiretroviral drug resistance in the treatment-naïve women 
was 14% (4 of 29). Three (10%) had evidence of TDR [187, 189] because mutations 
were observed at baseline. This prevalence of TDR is comparable with recent findings 
from a study in treatment-naïve adults in Honduras (7%), which was part of the 
Swedish-Honduran project [226]. One important fact that has to be highlighted is that 
the drug resistance associate mutations detected in 3 of the treatment-naïve women 
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conferred high level resistance to drugs that are commonly used in the country, i.e. 
3TC, EFV, NVP [225]. Surprisingly, a high proportion of treatment-naïve women 12 of 
29 (41%) had detectable HIV-1 RNA levels in samples collected a few days after 
delivery despite they were under antiretroviral prophylaxis. Six (21%) of these women 
had virus levels greater than 10,000 copies/ml. Our results show that the level of TDR 
and viral loads in treatment-naïve HIV-1 positive pregnant Honduran women is a great 
concern because it could limit the clinical effectiveness of ARV prophylaxis and 
indicates that there is a risk for MTCT [149].  
The prevalence of antiretroviral drug resistance in the treatment-experienced 
women was 30% (6 of 21), which is higher than prevalence’s reported in other 
American countries [230-232].  In all of them, the resistance-associated mutations was 
detected in the first sample collected during pregnancy, meaning, that resistance in 
those women is likely to be related to ongoing and previous ART. All women had high-
level resistance to both NNRTIs available in Honduras, i.e. NVP and EFV [225]. This 
was primarily due to the presence of the K103N mutation [169]. In addition, three 
women showed sign of NRTI resistance mutations. The M184V mutation, which is 
associated with high-level resistance to 3TC, was the most frequently observed NRTI 
mutation [182, 233]. Both NNRTIs and 3TC have a low genetic barrier towards 
resistance [180] and as they are widely used in Honduras [225], therefore it is not 
surprising to find a high frequency of resistance to these drug classes in the country. 
Thus, the relatively frequent observation of high-level resistance to these drugs in 
pregnant women is worrisome. Ten of the 21 (48%) treatment-experienced women had 
detectable HIV-1 RNA levels in samples collected a few days after delivery. Three 
(14%) had virus levels greater than 10,000 copies/ml, despite receiving ART at the time 
of baseline sample collection. Moreover, the treatment-experienced women with 
resistance had significantly higher virus levels at baseline than those without resistance 
(p=0.014; Mann-Whitney U-test).   
Collectively the findings in the naïve and treated women indicate that even 
though no cases of MTCT occurred, the degree of resistance together with the relatively 
high levels of ongoing viral replication show that there is a significant risk for MTCT 
in the population [149]. 
Some studies have found an association between microbial translocation and 
immune activation [96, 100, 234]. One marker of microbial translocation is the LPS in 
plasma, which have been measured in different HIV infected populations, but to our 
knowledge not earlier studied in HIV infected pregnant women. We found that plasma 
LPS levels were higher during pregnancy, than after delivery in HIV infected women 
(72 pg/ml, range 23 – 179 pg/ml vs. 46 pg/ml; range 13 – 98 pg/ml; p<0.001, Wilcoxon 
matched pairs test). Interestingly, there was no significant difference in LPS levels 
between pregnant HIV-positive and HIV-negative women during pregnancy (p = 0.38). 
This could indicate that microbial translocation may naturally increase during 
pregnancy. Nevertheless as the sample size is too small, further larger studies are 
needed to confirm our preliminary findings.  
In summary, this study shows for first time relatively high levels of antiretroviral 
drug resistance and ongoing viral replication in the context of antiretroviral prophylaxis 
and MTCT in Honduras. These findings needs to be considered as an alert indicator of 
the urgent need to improve the strategies to prevent MTCT in the country including: 1) 
improvement of antiretroviral prophylaxis regime; 2) availability of genotypic drug 
resistance tests which at the time is not implemented in the country; 3) better access of 
viral load test for pregnant women; 4) further studies to determine of rate of MTCT in 
the country that has been estimated to be around of 0.5%, but the real rate remains 
unknown. 
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10    CONCLUDING REMARKS AND FUTURE 
   PERSPECTIVES   
 
One of the most effective strategies to prevent MTCT of HIV is the use of 
antiretroviral prophylaxis during and after pregnancy. Additionally, ART has been 
proven to be beneficial to treat pregnant women for their own health [173].  
In Honduras, as in other developing countries, there was for a long time use of 
sub-optimal regimens to prevent MTCT. However, in 2008 this changed by the 
introduction of cART to prevent MTCT, which is considered the best strategy to 
minimize HIV transmission [170]. Despite that access to antiretroviral regimens have 
improved in recent years, very few studies have addressed the prevalence of 
antiretroviral drug resistance in Central America [225-229]. This includes Honduras 
where there was no prior information about HIV-1 drug resistance in pregnant women 
and their infants. As the development of antiretroviral drug resistance remains a major 
concern worldwide, this project was initiated to study different aspects of antiretroviral 
prophylaxis and resistance in Honduran pregnant women and infants.  Several 
important results have been obtained in the two papers presented in this thesis. Firstly, 
we have shown that the prevalence of antiretroviral drug resistance is relatively high in 
Honduran infants and pregnant women. Secondly, we found that many women were 
viremic despite antiretroviral prophylaxis against MTCT. Thus, MTCT of both wild-
type and resistant strains is an important threat in both Honduras and Belize that 
requires attention.  
Our findings show that it there is a need to improve access and turn-around time 
of viral load testing for pregnant Honduran women to determine the success or failure 
of ARV prophylaxis. Furthermore, it would be very valuable if resistance testing could 
be made available in Honduras in order to provide guidance for preventive treatment 
and treatment management. This would allow doctors to make timely and informed 
treatment decision for women with virological treatment failure.  
This project has provided new insights into the problem of HIV resistance, 
treatment, and MTCT that can support the health systems future decisions in relation to 
improving MTCT prevention strategies. The findings from these studies have raised the 
alert from the National health authorities and have contributed to strengthen the good 
collaboration with the physicians and other health personnel, such as nurses and 
psychologists, at the different hospitals and health centers and also with the National 
HIV/AIDS Program. This partnership and the relevance of these studies have generated 
an interest by both sides to continue the close collaboration to seek for grants for future 
studies in the field of HIV resistance. Through the project “Molecular Epidemiology of 
HIV-1 in Central American region and Drug Resistant in Honduras” a good 
collaboration with Belize, Guatemala, El Salvador, Nicaragua, Costa Rica, Panama and 
Ecuador has been established. Moreover, the implementation of new technology and 
the professional capacities of the personnel that has been generated through the 
collaboration between Karolinska Institutet and National Autonomous University of 
Honduras in this study permitted to strengthen the laboratory HIV testing in the country 
which is going to be beneficial in the future for HIV research in Honduras.  
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